{"analyses":[{"ciLowerLimit":"2.02","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.71","groupDescription":"Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"3.39","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.42","upperLimit":"19.60","value":"13.3"},{"groupId":"OG001","lowerLimit":"28.13","upperLimit":"38.64","value":"33.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"325"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"NUMBER","populationDescription":"Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the Global Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}